<DOC>
	<DOCNO>NCT00225056</DOCNO>
	<brief_summary>In phase II study , plan evaluate efficacy , safety tolerability weekly docetaxel capecitabine 21-day cycle follow maintenance single agent capecitabine treatment metastatic breast cancer , Based efficacy toxicity combination regimen dosages previously review ; weekly docetaxel 30mg/m2 day 1 8 plus capecitabine 1600mg/m2 ( 800mg/m2 orally twice daily ) day 1 14 cycle utilize .</brief_summary>
	<brief_title>Phase II Study Capecitabine Weekly Docetaxel Followed Capecitabine Maintenance Patients With Metastatic Breast Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>must metastatic breast cancer must cytologically pathologically confirm invasive ductal lobular carcinoma must measurable evaluable disease ECOG 01 patient may receive 0 , 1. 2 prior treatment metastatic breast cancer must adequate organ function must least 19 year age peripheral neuropathy less equal grade 1 must voluntarily sign informed consent patient brain metastasis eligible provide measurable disease exist brain lesion control patient malignancy , except non melanoma skin , evidence cancer within last 5 year patient psychiatric illness concurrent severe comorbid medical condition would preclude study completion know uncontrolled exist coagulopathy patient history severe hypersensitivity reaction docetaxel , medication formulate polysorbate 80 5fluorouracil use investigational agent last 28 day pregnant lactating woman patient know HIV positive patient life expectancy le 3 month sexually active patient unwilling practice reliable contraception study</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>